Log In Sign up
The largest database of trusted experimental protocols

Sepax 2rm device

Manufactured by Cytiva
Visit Supplier

The Sepax 2RM device is a closed, automated cell processing system designed for cell separation and washing applications. It provides a controlled environment for the processing of cell-based therapies and other biological materials. The device features pre-programmed protocols and enables the efficient and reproducible processing of cell samples.

Automatically generated - may contain errors

Lab products found in correlation

Clinimacs device, by Miltenyi Biotec (2 mentions) Rhil 15, by CellGenix (2 mentions) Knockout sr, by Thermo Fisher Scientific (2 mentions) Rhil 7, by CellGenix (2 mentions) Rhil 21, by Miltenyi Biotec (2 mentions) Cts dynabeads cd3 cd28, by Thermo Fisher Scientific (2 mentions) Cryostor cs5, by BioLife Solutions (2 mentions) X vivo 15, by Lonza (2 mentions)

2 protocols using sepax 2rm device

1

Anti-B7-H3 CAR-T Cell Production

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ and CD8+ T cells were isolated from patient apheresis products using the CliniMACS device (Miltenyi Biotec). A 1:1 mixture of CD4-enriched and CD8-enriched cell fractions were then pooled, suspended in X-Vivo 15 (Lonza) media supplemented with 2% KnockOut SR (Life Technologies), 5 ng/mL rhIL-7 (CellGenix), 0.5 ng/mL rhIL-15 (CellGenix) and 10 ng/mL rhIL-21 (Miltenyi Biotec), initiated into culture in a G-Rex 100MCS vessel (Wilson-Wolf), and stimulated using CD3/CD28 CTS® Dynabeads (Life Technologies). Cell products were then transduced with a GMP-grade SIN (self-inactivating) lentivirus encoding the anti-B7-H3CAR, the methotrexate-resistant human DHFR mutein huDHFRdm, and the cell-surface marker EGFRt. On day 3 of culture, 50nM methotrexate (Mylan) was added to the culture vessel to select for cells possessing DHFRdm. On day 7 of culture, CD3/CD28 CTS® beads were removed from the cell suspension using the Dynamag CTS device. Following 10–13 days in culture, patient cells were harvested and washed using the Sepax 2RM device (Cytiva) and resuspended in CryoStor-CS5 (Biolife Solutions) for cryopreservation in CellSeal closed-system vials (Sexton).
Vitanza N.A., Wilson A.L., Huang W., Seidel K., Brown C., Gustafson J.A., Yokoyama J.K., Johnson A.J., Baxter B.A., Koning R.W., Reid A.N., Meechan M., Biery M.C., Myers C., Rawlings-Rhea S.D., Albert C.M., Browd S.R., Hauptman J.S., Lee A., Ojemann J.G., Berens M.E., Dun M.D., Foster J.B., Crotty E.E., Leary S.E., Cole B.L., Perez F.A., Wright J.N., Orentas R.J., Chour T., Newell E.W., Whiteaker J.R., Zhao L., Paulovich A.G., Pinto N., Gust J., Gardner R.A., Jensen M.C, & Park J.R. (2022). Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discovery, 13(1), 114-131.
+ Open protocol
+ Expand
2

Engineered Antigen-Specific T Cell Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ and CD8+ T cells were isolated from patient apheresis products using the CliniMACS device (Miltenyi Biotec). A 1:1 mixture of CD4-enriched and CD8-enriched cell fractions were then pooled, suspended in X-Vivo 15 (Lonza) media supplemented with 2% KnockOut SR (Life Technologies), 5 ng/mL rhIL7 (CellGenix), 0.5 ng/mL rhIL15 (CellGenix), and 10 ng/mL rhIL-21 (Miltenyi Biotec), initiated into culture in a G-Rex 100MCS vessel (Wilson-Wolf), and stimulated using CD3/CD28 CTS Dynabeads (Life Technologies). Cell products were then transduced with a GMP-grade SIN (self-inactivating) lentivirus encoding the anti-B7-H3 CAR, the MTX-resistant human DHFR mutein huDHFRdm, and the cell-surface marker EGFRt. On day 3 of culture, 50 nmol/L MTX (Mylan) was added to the culture vessel to select for cells possessing DHFRdm. On day 7 of culture, CD3/CD28 CTS beads were removed from the cell suspension using the Dynamag CTS device. Following 10 to 13 days in culture, patient cells were harvested and washed using the Sepax 2RM device (Cytiva) and resuspended in CryoStor-CS5 (Biolife Solutions) for cryopreservation in CellSeal closed-system vials (Sexton).
Vitanza N.A., Wilson A.L., Huang W., Seidel K., Brown C., Gustafson J.A., Yokoyama J.K., Johnson A.J., Baxter B.A., Koning R.W., Reid A.N., Meechan M., Biery M.C., Myers C., Rawlings-Rhea S.D., Albert C.M., Browd S.R., Hauptman J.S., Lee A., Ojemann J.G., Berens M.E., Dun M.D., Foster J.B., Crotty E.E., Leary S.E., Cole B.L., Perez F.A., Wright J.N., Orentas R.J., Chour T., Newell E.W., Whiteaker J.R., Zhao L., Paulovich A.G., Pinto N., Gust J., Gardner R.A., Jensen M.C, & Park J.R. (2022). Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discovery, 13(1), 114-131.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!

  Request a quote for « Sepax 2rm device »